AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.
This article: 246 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE